[go: up one dir, main page]

AR054438A1 - Inhibidores de adn -pk - Google Patents

Inhibidores de adn -pk

Info

Publication number
AR054438A1
AR054438A1 ARP060101479A ARP060101479A AR054438A1 AR 054438 A1 AR054438 A1 AR 054438A1 AR P060101479 A ARP060101479 A AR P060101479A AR P060101479 A ARP060101479 A AR P060101479A AR 054438 A1 AR054438 A1 AR 054438A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
alkyl
attached
hydrogen
Prior art date
Application number
ARP060101479A
Other languages
English (en)
Inventor
Cameron Graeme Smith
Niall Morrison Martin
Keith Allan Menear
Marc Geoffrey Hummersone
Xiao Ling Cockcroft
Bernard Thomas Golding
Ian Robert Hardcastle
David Richard Newell
Hilary Alan Calvert
Nicola Jane Curtin
Roger John Griffin
Original Assignee
Kudos Pharm Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd filed Critical Kudos Pharm Ltd
Publication of AR054438A1 publication Critical patent/AR054438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) e isomeros, sales, solvatos, formas químicamente protegidas y prodrogas del mismo, donde: A, B y D se seleccionan respectivamente entre el grupo que consiste en (i) CH, NH, C; (ii) CH, N, N; y (ii) CH, O, C; la líneas punteadas representan dos doble enlaces en las ubicaciones apropiadas; RN1 y RN2 se seleccionan en forma independiente entre hidrogeno, un grupo C1-7 alquilo, C3-20 heterociclilo, o C5-20 arilo opcionalmente sustituido, o pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; Z2,Z3, Z4, Z5 y Z6, junto con el átomo de carbono al cual están unidos, forman un anillo aromático; Z2 se selecciona entre el grupo que consiste en CR2, N, NH, S, y O; Z3 es CR3; Z4 se selecciona entre el grupo que consiste en CR4, N, NH, S y O; Z5 es un enlace directo, o se selecciona entre el grupo que consiste en O, N, NH, S y CH; R2 es H; R3 se selecciona entre halo o C5-20 arilo opcionalmente sustituido; R4 se selecciona ente el grupo que consiste en H, OH, NO2 y Q-Y-X, donde Q es -NH-C(=O)- o -O-; Y es un grupo C1-5 alquileno opcionalmente sustituido; X se selecciona entre SRS1 o NRN3RN4, donde, RS1, o RN3 y RN4 se seleccionan en forma independiente entre hidrogeno, grupos C1-7 alquilo, C5-20arilo, o C3-20 heterociclilo opcionalmente sustituidos, o RN3 y RN4 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; si Q es -O-, X puede seleccionarse además ente -C(=O)-NRN5RN6, donde RN5 y RN6 se seleccionan en forma independiente entre hidrogeno, grupos C1-7 alquilo, C5-20arilo, o C3-20 heterociclilo opcionalmente sustituidos, o RN5 y RN6 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo y si Q es -NH-C(=O)-, -Y-X puede seleccionarse adicionalmente entre C1-7 alquilo. Composiciones farmacéuticas que los contienen y usos como agentes potenciadores de la quimioterapia y de la radioterapia, en el tratamiento del cáncer.
ARP060101479A 2005-04-15 2006-04-12 Inhibidores de adn -pk AR054438A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67188605P 2005-04-15 2005-04-15
US67183005P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20

Publications (1)

Publication Number Publication Date
AR054438A1 true AR054438A1 (es) 2007-06-27

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101479A AR054438A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn -pk
ARP060101480A AR053358A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn - pk

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060101480A AR053358A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn - pk

Country Status (13)

Country Link
US (2) US7696203B2 (es)
EP (2) EP1869040A1 (es)
JP (2) JP2008535902A (es)
KR (1) KR20080002963A (es)
AR (2) AR054438A1 (es)
AU (1) AU2006235731A1 (es)
CA (1) CA2603637A1 (es)
IL (1) IL186445A0 (es)
MX (1) MX2007012696A (es)
NO (1) NO20075809L (es)
TW (2) TW200720274A (es)
UY (1) UY29479A1 (es)
WO (2) WO2006109084A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
CN1867566B (zh) * 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
CN101061111A (zh) 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
SG10201403138WA (en) * 2009-07-02 2014-08-28 Sanofi Sa Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof
JP5680639B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規６−モルホリン−４−イル−ピリミジン−４−（３ｈ）−オン誘導体、およびａｋｔ（ｐｋｂ）リン酸化阻害剤としてのこの医薬調製物
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
MX2012000103A (es) 2009-07-02 2012-05-22 Sanofi Sa Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica.
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
SG177469A1 (en) 2009-07-02 2012-02-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
MX341957B (es) 2010-04-15 2016-09-08 3M Innovative Properties Co Articulos retrorreflectantes que incluyen areas opticamente activas y areas opticamente inactivas.
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
IN2014KN02601A (es) 2012-04-24 2015-05-08 Vertex Pharma
US9340536B2 (en) * 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
PT2970218T (pt) 2013-03-12 2019-03-01 Vertex Pharma Inibidores de adn-pk
CA2968090A1 (en) 2014-12-02 2016-06-09 Prana Biotechnology Limited 4h-pyrido[1,2-a]pyrimidin-4-one compounds
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
WO2021184014A1 (en) * 2020-03-13 2021-09-16 Arizona Board Of Regetns On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (es) 1969-05-14 1973-01-17
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
EP0459983A1 (en) 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
DE69127690T2 (de) 1990-06-20 1998-02-12 Pharmacia & Upjohn Company Kal Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
JPH05501886A (ja) 1990-06-29 1993-04-08 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性２―アミノ―６―フェニル―４ｈ―ピラン―４―オン類
US5252735A (en) 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
DE69327153T2 (de) 1992-09-02 2000-05-25 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv-medikament
JP3521145B2 (ja) 1993-04-09 2004-04-19 富山化学工業株式会社 免疫調節剤，細胞接着阻害剤および自己免疫疾患の治療・予防剤
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1997018323A2 (en) 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
DE60128655T2 (de) * 2000-01-24 2008-02-07 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
CN1867566B (zh) * 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
CN101061111A (zh) 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
JP2008529995A (ja) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
KR20080002963A (ko) 2008-01-04
MX2007012696A (es) 2008-03-14
WO2006109081A1 (en) 2006-10-19
US7696203B2 (en) 2010-04-13
EP1869021A1 (en) 2007-12-26
WO2006109084A1 (en) 2006-10-19
JP2008535902A (ja) 2008-09-04
AR053358A1 (es) 2007-05-02
UY29479A1 (es) 2006-11-30
IL186445A0 (en) 2008-01-20
JP2008535903A (ja) 2008-09-04
US20060264427A1 (en) 2006-11-23
TW200720274A (en) 2007-06-01
EP1869040A1 (en) 2007-12-26
TW200720271A (en) 2007-06-01
AU2006235731A1 (en) 2006-10-19
US20060264623A1 (en) 2006-11-23
NO20075809L (no) 2007-12-27
CA2603637A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AR054438A1 (es) Inhibidores de adn -pk
CR11546A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
ECSP099728A (es) Compuestos amino-heterocíclicos
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
AR062786A1 (es) Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.
DOP2010000046A (es) Compuestos de biciclolactama sustituida
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
ECSP045073A (es) Nuevos derivados de piperazina
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
TW200640462A (en) Compounds
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal